Detalles de la búsqueda
1.
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
Br J Haematol
; 204(3): 877-886, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37952982
2.
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine.
Ther Adv Hematol
; 15: 20406207241257904, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38883163
3.
Quantification of azacitidine incorporation into human DNA/RNA by accelerator mass spectrometry as direct measure of target engagement.
J Pharm Biomed Anal
; 202: 114152, 2021 Aug 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34051483
4.
Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy.
Leukemia
; 37(1): 240-243, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36437356
Resultados
1 -
4
de 4
1
Próxima >
>>